1. Search Result
Search Result
Results for "

Hla

" in MedChemExpress (MCE) Product Catalog:

63

Inhibitors & Agonists

47

Peptides

6

Inhibitory Antibodies

2

Natural
Products

136

Recombinant Proteins

2

Isotope-Labeled Compounds

13

Antibodies

26

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P10662

    Peptides Infection Inflammation/Immunology
    HLA-B*0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B*0801-binding EBV peptide can bind to the HLA-B*0801 molecule. HLA-B*0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response .
  • HY-P10593

    Peptides Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
  • HY-P2507

    Peptides Cancer
    NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4 + T cells when presented in the context of HLA-DR and HLA-DP4 molecules .
  • HY-P5294

    EBV Cancer
    YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .
  • HY-P4667

    Peptides Metabolic Disease
    VLHDDLLEA is a peptide that can be isolated from the MHC complex HLA-A*0201 molecule. VLHDDLLEA can be recognized by HLA-A*0201-restricted cytotoxic T cells (CTLs). VLHDDLLEA can be used for research on graft versus host disease (GvHD) .
  • HY-P1700

    TNF Receptor Cancer
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .
  • HY-P10339

    Peptides Inflammation/Immunology
    SMCY peptide inhibits the binding of iodinated standard peptide to HLA-B7 with an IC50 of 34 nM. As an epitope of the H-Y antigen, SMCY peptide can be presented by the HLA-B7 molecule and recognized by specific T cells, leading to transplant rejection .
  • HY-P1780

    CMV Infection
    CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).
  • HY-P4628

    LRH-1 peptide

    Peptides Inflammation/Immunology
    TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. TPNQRQNVC induces a CD8+ T cell immune response .
  • HY-P1881

    HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
  • HY-P5476

    Peptides Others
    Influenza virus NP (44-52) is a biological active peptide. (HLA-A*01 restricted epitope from influenza virus nucleoprotein (44-52).)
  • HY-P5477

    Peptides Others
    Influenza virus NP (266-274) is a biological active peptide. (HLA-A*03 restricted epitope from influenza virus nucleoprotein (265-274).)
  • HY-P1842

    Peptides Cancer
    MAGE-A3 (195-203) is a human leukocyte antigen (HLA) -A24 molecules epitope encoded by melanoma antigen gene (MAGE) .
  • HY-P1757

    HIV Infection
    HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .
  • HY-P1890

    EBV Infection
    CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).
  • HY-106187

    Peptides Inflammation/Immunology
    MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .
  • HY-P5478

    DNA/RNA Synthesis Influenza Virus Others
    Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)
  • HY-P10664

    EBV Inflammation/Immunology
    EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .
  • HY-P3644

    Peptides Cancer
    EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5 .
  • HY-P10663

    EBV Infection Inflammation/Immunology
    EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 + T cell response in HLA-B*07:02 + individuals .
  • HY-P5482

    EBV Others
    Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)
  • HY-P1901

    Peptides Metabolic Disease
    Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain .
  • HY-P5475

    EBV Others
    BMLF1 (280–288) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288).)
  • HY-P1919

    Peptides Cancer
    Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .
  • HY-P5470

    EBV Others
    LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)
  • HY-P3813

    Tyrosinase Inflammation/Immunology Cancer
    Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .
  • HY-P1857

    Influenza Virus Infection
    CEF7, Influenza Virus NP (380-388) is a HLA-B *08 restricted influenza virus nucleoprotein epitope. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .
  • HY-P10264

    MAGE-3(168-176), human

    Peptides Cancer
    MAGE-3 peptide (MAGE-3 168-176, human) is a peptide encoded by human MAGE-3 gene, which is expressed in tumor cells, presented by HLA and recognized by cytolytic T lymphocytes (CTL) as tumor antigen .
  • HY-P0277

    CEA peptide

    Peptides Cancer
    Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers .
  • HY-P1778

    HPV Infection
    HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
  • HY-P3640

    Peptides Cancer
    MAGE-3 Antigen (167-176) (human) is a polypeptide containing eight amino acids. MAGE-3 Antigen (167-176) (human) is a human leukocyte antigen HLA-B44 molecules epitope encoded by melanoma antigen gene (MAGE) .
  • HY-P3742

    Peptides Cancer
    Tyrosinase (192-200), human mouse is a nonapeptide. Tyrosinase (192-200), human mouse can be recognized by cytolytic T cell (CTL) on the HLA-B44 molecule. Tyrosinase (192-200), human mouse can be used in research of melanoma associated cancers .
  • HY-P1835

    Influenza Virus Inflammation/Immunology
    CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B *2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity .
  • HY-P1778A

    HPV Infection
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
  • HY-P1914

    Peptides Cancer
    NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1 .
  • HY-P1855

    EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .
  • HY-P5425

    Peptides Others
    Tetanus Toxin (830–844) is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population)
  • HY-P3248

    Myelin basic protein (85-99) antagonist

    Biochemical Assay Reagents Inflammation/Immunology
    J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP85-99 to HLA-DR2. J5 peptide alleviates PLP139-151/MBP85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .
  • HY-P1826

    Peptides Inflammation/Immunology Cancer
    CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site .
  • HY-P1826A

    Peptides Inflammation/Immunology Cancer
    CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site .
  • HY-P4032

    HCV Inflammation/Immunology
    HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
  • HY-P2524

    Peptides Cancer
    MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .
  • HY-P5503

    HIV Others
    Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)
  • HY-P10493

    Amino Acid Derivatives Cancer
    NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
  • HY-P10493A

    Amino Acid Derivatives Cancer
    NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
  • HY-P10835

    LAG-3 Cancer
    LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
  • HY-P5471

    [Leu27]-Melan-A, MART-1 (26-35)

    Peptides Others
    Melan-A/MART-1 analog ([Leu27]-Melan-A, MART-1 (26-35)) is a biological active peptide. (This Melan-A (26-35) analog, Leu substituted for Ala at position 27, shows better HLA-A*0201 binding properties as well as better immunogenicity and antigenicity than the natural Melan-A (26-35).Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: